register free | resend password

PAREXEL Expands Global Regulatory Services with Addition of Senior Executives from FDA and Oncology Industry

New Appointments Enhance PAREXEL’s Leadership and Expertise in Bringing Commercially Viable, Reimbursable Products to Market

ID: 1528914
recent pressrelease next pressrelease

(businesspress24) - New Appointments Enhance PAREXEL’s Leadership and Expertise in Bringing Commercially Viable, Reimbursable Products to Market

BOSTON, November 15, 2017 - PAREXEL, a leading global biopharmaceutical services provider, today announced the appointment of three former senior regulatory consulting executives from the U.S. Food and Drug Administration (FDA) and Oncology industry positions. The new hires are part of PAREXEL’s Global Integrated Product Development and Compliance team and will be focused on helping PAREXEL clients deliver commercially viable, reimbursable products to market faster and more cost-effectively.

Robert Iser, Vice President of Regulatory Consulting Service: Mr. Iser joins PAREXEL from his post as Director of the FDA’s Office of Process & Facilities, and will be focused on helping clients avoid market delays due to compliance or quality problems. Over more than 14 years with the agency, Mr. Iser reviewed product quality and assessed manufacturing processes and pre-approval inspections, and was responsible for developing and implementing CMC guidance. Prior to joining the FDA, he spent seven years in the pharmaceutical industry managing quality systems, and supporting manufacturing process development, scale-up, and validation.

Dr. Bob (Bhardwaj) Desai, Vice President of Consulting, Technical (Oncology): With more than 10 years of experience leading global oncology and biologic/biosimilar drug development programs for Astellas Oncology, Pfizer, Hospira, and Abbott/Abbvie, Dr. Desai’s expertise extends to all phases of oncology drug development and all product classes, from chemical compounds to recombinant biologics, including mAbs, biosimilars and antibody drug conjugates (ADCs). Dr. Desai has worked closely with the FDA and other global regulatory authorities to expedite the review and approval of multiple compounds, including a successful oral presentation to the European Medicines Agency (EMA) for the approval of the first biosimilar monoclonal antibody.

Dr. Chang Lee, Vice President of Consulting, APAC: Dr. Lee brings both industry and regulatory agency experience to PAREXEL. He led Regulatory and Clinical Affairs at Capsugel, KV Pharmaceuticals, Morton Grove Pharmaceuticals, TAP Pharmaceutical Products Inc., Novartis OTC, and Igenix, and served as a Medical Officer at the FDA’s Center for Drug Evaluation. U.S. board-certified in Clinical Pathology, he is knowledgeable in global clinical and regulatory product development, including risk management, and has worked with many global regulatory authorities, including FDA, EMA, the Medicines and Healthcare products Regulatory Agency (MHRA), Health Canada, the Central Drugs Standard Control Organization (CDSCO) in India, and the China Food and Drug Administration (CFDA).

These new team members join other recent additions to the PAREXEL Consulting, Integrated Product Development teams, including former FDA Clinical Team Leader Ron Farkas, Vice President, Technical.

“At PAREXEL, our approach to drug development necessitates an integrated strategy that demonstrates product value and mitigates risk. As such, we are always focused on building a robust team with global and diverse expertise,” said Dr. Paul Bridges, Worldwide Head of PAREXEL Consulting. “These new team members will contribute to our mission of helping clients take their products through development swiftly, successfully, and profitably, and ultimately, to the patients who need them most.”

More information:

Keywords (optional):

parexel, biopharmaceutics, fda, appointment,

Company information / Profile:

PressRelease by


PressContact / Agency:

Jenny Radloff, PAN Communications
Tel.: +1 617-502-4300
Email: PAREXEL(at)

published by: RealWire
print pressrelease  send to a friend  

Date: 11/15/2017 - 16:40
Language: English
News-ID 1528914
Character count: 3703
Firma: RealWire
Ansprechpartner: Leah Wood Feedback to about Pressrelease-id:
Stadt: Lincoln
Telefon: 1522883640

Meldungsart: bitte
Versandart: Veröffentlichung
Freigabedatum: 15/11/2017

Number of hits: 765


Direct Link to this PressRelease:

We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease

All members: 9 438
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 63

Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.